, {

Attorney Docket No.: 019633-0001

Client Reference No.: 1098

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

GILBERT and WAKARCHUK

Application No.:

Filed: Herewith

For: NUCLEIC ACIDS ENCODING BETA-1,4-GALNAC TRANSFERASE Examiner: Unassigned

Art Unit: Unassigned

INFORMATION DISCLOSURE

STATEMENT UNDER 37 CFR §1.97 and

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Also enclosed is a copy of the Search/Examination report corresponding to the PCT application.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Beth L. Kelly Reg. No. 51,868

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, 8<sup>th</sup> Floor San Francisco, California 94111-3834 Tel: 415-576-0200

Fax: 415-576-0300

BLK/llc SF 1404050 v1

DTO.	(CD MAD	(10-01)	

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO	Complete if Known			
INCORMATION DISCLOSURE	Application Number			
INFORMATION DISCLOSURE	Filing Date	Herewith		
STATEMENT BY APPLICANT	First Named Inventor	Gilbert, Michel, et. al.		
	Art Unit	Unassigned		
(use as many sheets as necessary)	Examiner Name	Unassigned		
Sheet 1 of 2	Attorney Docket Number	019633-000112US		

			U.S. PATENT D	OCUMENTS	
		Document Number	•		
Examiner	Cite No. <sup>1</sup>	Number Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US-5,352,670	10-04-1994	Venot, et al.	· iga oo i epodi
	AB	US-5,374,541	12-20-1994	Wong, et al.	
	AC	US-5,545,553	08-13-1996	Gotschlich	
		US-	-		- · · · · · · · · · · · · · · · · · · ·

				FOREIGN PA	TENT DOCUM	ENTS		
Examiner	Cite	For	eign Patent Doo	cument		Name of Patentee or	Pages, Columns, Lines,	1
Initials*	No.1	Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>s</sup> (if known)	Publication Date MM-DD-YYYY	Applicant of Cited  Document	Where Relevant Passages or Relevant Figures Appear	T⁵
	AD	wo	92/16640		10-01-1992	The Scripps Research Institute		
	AE	wo	96/32491		10-17-1996	Cytel Corp.		
	AF	wo	99/49051	A1	09-30-1999	National Research Council of Canada		

OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS								
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²					
	AG	ASPINALL et al., "Lipopolysaccharides of Campylobacter jejuni Serotype O:19: Structures of Core Oligosaccharide Regions from the Serostrain and Two Bacterial Isolates from Patients with the Guillain-Barré Syndrome" Biochemistry, 33: 241-249 (1994b)						
	АН	ASPINALL et al., *Lipopolysaccharides of Campylobacter jejuni Serotype O:19: Antigen Chains from the Serostrain and Two Bacterial Isolates from Patients with the Guillain-Barré Syndrome* Biochemistry, 33: 250-255 (1994c)						
	Al	ASPINALL, et al. " Chemical Structures of the Core Regions of Campylobacter Jejuni Serotypes 0:1, 0:4, 0:23, and 0:36 Lipopolysaccharides," European Journal of Biochemistry, Vol. 213, No. 3, pp. 1017-1027, (May 1993)						
	ĄJ	ASPINALL, et al. "Lipopolysaccharides from Campylobacter Jejuni Associated with Guillain-Barré Syndrome Patients Mimic Human Gangliosides in Structure," Infection and Immunity, Vol. 62, No. 5, pp. 2122-2125, (May 1994)						
	AK	BELUNIS et al., "Biosynthesis of Endotoxin" J. Biol. Chem., 267: 9988-9997 (1992)						
	AL	GAUDINO et al., "A Novel and Efficient Synthesis of Neolacto Series Gangliosides 3'-nLM1 and 6'-nLM1 " J. Am. Chem. Soc., 116: 1149-1150 (1994)						

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. SF 1404050 v1

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete if Known		
INFORMATION DISCLOSURE	Application Number			
· · · · · · · · · · · · · · · · · · ·	Filing Date	Herewith		
STATEMENT BY APPLICANT	First Named Inventor	Gilbert, Michel, et. al.		
	Art Unit	Unassigned		
(use as many sheets as necessary)	Examiner Name	Unassigned		
Sheet 2 of 2	Attorney Docket Number	019633-000112US		

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	АМ	GILBERT et al., "Cloning of the Lipooligosaccharide g-2,3-Sialyttransferase from the Bacterial Pathogens Neisseria Meningitidis and Neisseria Gonorrhoeae", "Journal of Biological Chemistry, Vol. 271, No. 45, pp. 28271-28276, The American Society for Biochemistry and Molecular Biology, Inc., USA, (November 8, 1996)	
	AN	GILBERT, et al., "Biosynthesis of Ganglioside Mimics in Campylobacter Jejuni OH4384," The Journal of Biolofical Chemistry, Vol. 275, No. 6, pp. 3896-3906, The American Society for Biochemistry and Molecular Biology, Inc., USA, (February 11,2000)	
	AO	ITO et al., "Synthesis of Bioactive Sialosides" Pure Appl. Chem., 65: 753 (1993)	
	AP	KUROKI, *Campylobacter jejuni Strains from Patients with Guillain-Barré Syndrome Belong Mostly to Penner Serogroup 19 Contain β-N-Acetylglucosamine Residues* Ann. Neurol., 33: 243-247 (1993)	
	AQ	PARKHILL, et al. "The Genome Sequence of the Food-Borne Pathogen Campylobacter Jejuni Reveals Hypervariable Sequences," Nature, Vol. 403, pp. 665-668, (February 10, 2000)	
	AR	PENNER, et al., "Diversity of Lipopolysaccharide Structures in Campylobacter Jejuni," The Journal of Infectious Diseases, Vol. 176, No. 2, pp. S135-S138, (December 1997)	
	AS	PRENDERGAST, et al., "Lipopolysaccharides form Campylobacter Jejuni O:41 Strains Associated with Guillain- Barré Syndrome Exhibit Mimicry of GM1 Ganglioside," Infection and Immunity, Vol. 66, No. 8, pp. 3649-3677, (August 1998)	
	AT	PRESTON, et al., "The Lipooligosaccharides of Pathogenic Gram-Negative Bacteria," Critical Reviews in Microbiology, Vol. 22. No. 3, pp. 139-180, (1996)	
	AU	SABESAN et al., "Combined Chemical and Enzymatic Synthesis of Sialyloligosaccharides and Characterization by 500-MHz 1H and C NMR Spectroscopy" J. Am. Chem. Soc., 108: 2068-2080 (1986)	
	AV	SALLOWAY, et al., "Miller-Fisher Syndrome Associated with Campylobacter Jejuni Bearing Lipopolysaccharide Molecules that Mimie Human Ganglioside GD3," Infection and Immunity, Vol. 64, No. 8, pp. 2945-2949, (August 1996)	
	AW	WAKARCHUK et al., "Functional Relationships of the Genetic Locus Encoding the Glycosyltransferase Enzymes Involved in Expression of the Lacto-N-neotetraose Terminal Lipopolysaccharide Structure in Neisseria meningitidis" J. Biol. Chem., 271: 19166-19173 (1996)	
	AX	WOOD, et al., "Cloning, Mutation and Distribution of a Putative Lipopolysaccharide Biosynthesis Locus in Campylobacter Jejuni," Microbiology, Vol. 145, No. 2, pp. 379-388, (February 1999)	

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. SF 1404050 v1



<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Attorney Docket No.: 019633-000112US Client Reference No.: 10983-1A

Assistant Commissioner for Patents Washington, D.C. 20231

on\_\_\_\_\_2/27/03

TOWNSEND and TOWNSEND and CREW

By: Fandon Clark

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

GILBERT and WAKARCHUK

Application No.: 10/303,128

Filed: November 21, 2002

For: NUCLEIC ACIDS ENCODING BETA-1,4-GALNAC TRANSFERASE

Examiner: Unassigned

Art Unit: 1652

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37

CFR §1.97 and §1.98

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Also enclosed is a copy of the Search/Examination report corresponding to the PCT application.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

Page 2

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that <u>no fee is required</u> for submission of this statement.

However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Act L Willy Beth L. Kelly

Reg. No. 51,868

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, 8<sup>th</sup> Floor San Francisco, California 94111-3834

Tel: 415-576-0200 Fax: 415-576-0300

BLK/llc SF 1436766 v1

PT	O/SB/	<b>'08B</b>	(10-01)	

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Substitute	for form 1449E	B/PTO		Complete if Known				
	INIEO	DMATIC	M DIC	CLOCUDE	Application Number	10/303,128			
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT  Application Number 10/303 Filing Date Novem First Named Inventor Gilbert Art Unit 1652  Examiner Name Unass	November 21, 2002							
		PPLICANT	First Named Inventor	Gilbert, Michel, et. al.					
	•				Art Unit	1652			
	(use as many sheets as necessary)				Examiner Name	Unassigned			
	Sheet	1	of	1	Attorney Docket Number	019633-000112US			

				<b>FOREIGN PA</b>	TENT DOCUM	ENTS		
Examiner Initials*	Cite No.1	Country Code <sup>3</sup>	eign Patent Doc Number <sup>4</sup>	Kind Code <sup>4</sup> (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T¢.
	AA	wo	00/46379	A1	08-10-2000	Gilbert, et al.		
		<del> </del>						
		<del> </del>						
		ļ						<u> </u>
								ļ
								<u> </u>
		<u> </u>						<u> </u>
		<del>                                     </del>	<del></del>					
		<del></del>						<u> </u>
		<del> </del>	<del></del>					
		<del> </del>		<del></del>				├
		<del> </del>	-					<b>├</b>
		<del>                                     </del>	· · · · · · · · · · · · · · · · · · ·					<b> </b>
		<del>                                     </del>		· · · · · · · · · · · · · · · · · · ·				<u> </u>
		<del>                                     </del>		<del></del>				
		-						<del>                                     </del>
		<del> </del>						├
		<del> </del>						<del> </del> —
		<del> </del>						-
		<del> </del>			- 37 -			├
		<del>                                     </del>	-				<del></del>	├
		<del> </del>			-			<del> </del>
		<del> </del>					<u></u>	<del> </del>

Examiner	Date	
Signature	Considere	d

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SF 1436766 v1

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

OTPE VC.,

	PTO/SB/04B (10-01)
44	

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid CMB control number

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Compl te if Kn wn				
Applicati n Number	10/303,128			
Filing Date	November 21, 2002			
First Named Inventor	Gilbert, Michel, et. al.			
Art Unit	1652			
Examiner Name	Unassigned			
Attorney Docket Number	019633-000112US			

	FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	For Country Code <sup>3</sup>	eign Patent Doo Number <sup>4</sup>	Wind Code <sup>®</sup> (if known)	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T*	
95	AA	WO	00/46379	A1	08-10-2000	Gilbert, et al.	приев преви	10	
_0_		<del>  """                                 </del>	50.40570		00-10-2000	Calcold Of Gr.	<del> </del>	<del>1 H</del>	
								16	
		<del></del>				<del></del>	<del> </del>	1 -	
		1						10	
	<b> </b>	<b></b>			<del></del>				
		ļ					- MI	<b>)</b>	
	<b> </b>	<del> </del>				<u>Q</u>	ECEIA P	4-	
	<del> </del>	<del> </del>	· · · · · · · · · · · · · · · · · · ·				2003		
	<del> </del>	<del> </del>					MAR 0 7 2003	<del></del>	
		<del> </del>					4CODI2	<del>aho</del> -	
	<del> </del>	<del> </del>				450	TI CENTER JOUGE	<del>770</del>	
						151	HCENTER 1600 2	+	
	<del>                                     </del>	1					<del> </del>	+	
		<b></b>					<del>                                     </del>	1-	
							<del> </del>	1	
								1	
								T	

Examiner				
Signature Considered IIVO 04	Examiner Signature	Ja Van C	Date Considered	11604

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SF 1436768 v1

+

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

# Notice of References Cited

Application/Control No.

10/303,128

Examiner

Sheridan L. Swope

Applicant(s)/Patent Under
Reexamination
GILBERT ET AL.

Art Unit
Page 1 of 1

#### **U.S. PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	Α	US-			
	В	US-			
	С	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	н	US-			
	ı	US-			
	J	US-			
	к	US-			
	L	US-			
	М	US-			

#### **FOREIGN PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	0					
	Р					
	Q					
	R					
	S					
	Т					

#### **NON-PATENT DOCUMENTS**

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Ausubel et al Protein Expression In: Current Protocols in Molecular Biology Wiley and Sons, Inc. 1987 Chapter 16.
	٧	Tomb et al The complete genome sequence of the gastric pathogen Helicobacter pylori. Swiss-Prot Acc#A64547. Alignment with SEQ ID NO: 17.
	w	
	х	

\*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)

Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

# PATENT COOPERATION TREATY

# **PCT**

# INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference  FOR FURTHER see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.  ACTION					
International application No.	International filing date (day/month/year)	(Earliest) Priority Date (day/month/year)			
PCT/CA 02/00229 22/02/2002 21/03/2001					
Applicant  NATIONAL RESEARCH COUNCIL	OF CANADA				
according to Article 18. A copy is being tra					
	international search was carried out on the bar less otherwise indicated under this item.	sis of the international application in the			
Authority (Rule 23.1(b)).	as carried out on the basis of a translation of t				
b. With regard to any nucleotide an was carried out on the basis of th		nternational application, the international search			
	onal application in written form.				
	ernational application in computer readable for	n.			
	o this Authority in written form.				
<u> </u>	o this Authority in computer readble form. bsequently furnished written sequence listing c	loes not go beyond the disclosure in the			
	as filed has been furnished.				
the statement that the infe	ormation recorded in computer readable form i	s identical to the written sequence listing has been			
2. Certain claims were fou	ind unsearchable (See Box I).				
3. Unity of invention is lac	sking (see Box II).				
4. With regard to the title,					
X the text is approved as su	ubmitted by the applicant.				
the text has been establis	shed by this Authority to read as follows:				
5. With regard to the abstract,					
	ubmitted by the applicant.				
the text has been establi within one month from th	shed, according to Rule 38.2(b), by this Author e date of mailing of this international search re	ity as it appears in Box III. The applicant may, port, submit comments to this Authority.			
	olished with the abstract is Figure No.	1			
X as suggested by the app	licant.	None of the figures.			
because the applicant fai	iled to suggest a figure.				
because this figure bette	r characterizes the invention.				

#### INTERNATIONAL SEARCH REPORT

International Application No PCT/CA 02/00229

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C12N9/10 C12N C12N9/12 C12Q1/68 C12N15/54 C12N5/10 According to International Patent Classification (IPC) or to both national classification and IPC **B. FIELDS SEARCHED** Minimum documentation searched (classification system followed by classification symbols) IPC 7 C12N Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, BIOSIS, SEQUENCE SEARCH C. DOCUMENTS CONSIDERED TO BE RELEVANT Category ° Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. X WO 00 46379 A (CANADA NAT RES COUNCIL) 1 - 4210 August 2000 (2000-08-10) the whole document Further documents are listed in the continuation of box C. Patent family members are listed in annex. Special categories of cited documents: "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the \*A\* document defining the general state of the art which is not considered to be of particular relevance invention earlier document but published on or after the international "X" document of particular relevance; the claimed invention filing date cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date but later than the priority date claimed "&" document member of the same patent family Date of the actual completion of the international search Date of mailing of the international search report 8 November 2002 19/11/2002 Name and mailing address of the ISA Authorized officer European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016 Strobel, A

2

### INTERNATIONAL SEARCH REPORT

International Application No
PCT/CA 02/00229

	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	1-
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GILBERT M ET AL: "BIOSYNTHESIS OF GANGLIOSIDE MIMICS IN CAMPYLOBACTER JEJUNI OH4384 IDENTIFICATION OF THE GLYCOSYLTRANSFERFERASE GENES, ENZYMATIC SYNTHESIS OF MODEL COMPOUNDS, AND CHARACTERIZATION OF NANOMOLE AMOUNTS BY 600-MHZ 1H AND 13C NMR ALAYSIS" JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 275, no. 6, 11 February 2000 (2000-02-11), pages 3896-3906, XP000893010 ISSN: 0021-9258 the whole document	1-42
X	WOOD A C ET AL: "CLONING, MUTATION AND DISTRIBUTION OF A PUTATIVE LIPOPOLYSACCHARIDEBIOSYTHESIS LOCUS IN CAMPYLOBACTER JEJUNI" INT. CONF. ON ALGORITHMS & ARCHITECTURES FOR PARALLEL PROCESSING, XX, XX, vol. 145, no. 2, February 1999 (1999-02), pages 379-388, XP000892785 page 382 -page 387, left-hand column, paragraph 2	1-42
A	PARKHILL J ET AL: "THE GENOME SEQUENCE OF THE FOOD-BORNE PATHOGEN CAMPYLOBACTER JEJUNIREVEALS HYPERVARIABLE SEQUENCES" NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 403, 10 February 2000 (2000-02-10), pages 665-668, XP000906767 ISSN: 0028-0836	1-42
X	the whole document & HTTP://WWW.SANGER.AC.UK/PROJECTS/C_JEJUNI/ ,	1-42

#### INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/CA 02/00229

Patent document cited in search report		Publication date	,	Patent family member(s)	Publication date
WO 0046379	Α	10-08-2000	AU WO EP US	2274300 A 0046379 A1 1147200 A1 2002042369 A1	25-08-2000 10-08-2000 24-10-2001 11-04-2002